Autochthonous T cells to the rescue: IL-10 directly activates tumor-resident CD8(+) T cells.
Oncoimmunology
; 1(9): 1637-1639, 2012 Dec 01.
Article
em En
| MEDLINE
| ID: mdl-23264920
ABSTRACT
Successful cancer immunotherapy is thought to require de novo priming of tumor specific CD8(+) T cells in lymphatic organs. Contrasting these beliefs, cancer therapy based on interleukin-10 (IL-10) results in tumor rejection without a requirement for T-cell trafficking from lymphatic organs. Rather, IL-10 directly activates autochthonous, tumor-resident CD8(+) T cells.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
Oncoimmunology
Ano de publicação:
2012
Tipo de documento:
Article
País de afiliação:
Irlanda